Valuation: Vaxart, Inc.

Market Cap 116M 103M 95.3M 86.25M 162M 10.9B 164M 1.14B 448M 5.73B 433M 424M 18.26B P/E 2026 *
-2.97x
P/E 2027 * -0.56x
Enterprise Value 116M 103M 95.3M 86.25M 162M 10.9B 164M 1.14B 448M 5.73B 433M 424M 18.26B EV / Sales 2026 *
0.97x
EV / Sales 2027 * 49.2x
Free-Float
98.52%
Yield 2026 *
-
Yield 2027 * -
1 day+0.63%
1 week+32.25%
Current month+34.20%
1 month+24.26%
3 months+20.78%
6 months-20.53%
Current year+74.34%
1 week 0.44
Extreme 0.44
0.62
1 month 0.4
Extreme 0.4
0.62
Current year 0.34
Extreme 0.3434
0.84
1 year 0.3
Extreme 0.305
0.84
3 years 0.26
Extreme 0.2606
1.54
5 years 0.26
Extreme 0.2606
8.13
10 years 0.25
Extreme 0.2543
24.9
Manager TitleAgeSince
Chief Executive Officer 60 18/03/2024
Chief Tech/Sci/R&D Officer 59 01/03/2024
Director of Finance/CFO - 19/05/2025
Director TitleAgeSince
Director/Board Member 68 21/04/2021
Director/Board Member 76 04/08/2022
Director/Board Member 79 01/01/2022
Date Insider Type Main position Quantity % Market Cap. Importance
7/16/26 A Free

Director

118,100 0.0488%
7/16/26 A Free

Director

118,100 0.0488%
7/16/26 A Free

Director

118,100 0.0488%
Change 5-day change 1-year change 3-year change Capi.($)
+0.63%+32.25%+70.11%-10.67% 119M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+6.12%+30.46%+50.05% 44.09B
+0.51%+10.71%+21.30%+133.92% 43.72B
-1.15%+3.10%+259.71%+594.60% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average +0.32%+4.30%+53.75%+109.63% 38.76B
Weighted average by Cap. +0.32%+4.67%+51.29%+127.73%

Financials

2026 *2027 *
Net sales 119M 106M 97.85M 88.55M 167M 11.19B 169M 1.17B 460M 5.88B 445M 436M 18.75B 2.35M 2.09M 1.94M 1.75M 3.31M 222M 3.34M 23.25M 9.12M 117M 8.82M 8.63M 371M
Net income -47.2M -42.06M -38.94M -35.24M -66.39M -4.45B -67.18M -467M -183M -2.34B -177M -173M -7.46B -222M -197M -183M -165M -312M -20.91B -315M -2.19B -860M -10.99B -831M -814M -35.02B
Net Debt - -
Projected Income Statement - Annual - Vaxart, Inc.
Logo Vaxart, Inc.
Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. The Company’s development programs include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), its first immune-oncology indication. The Company's platform technology employs a vector-based approach and consists of various components, such as vector, antigen, and adjuvant. A vector is a virus used as a carrier to deliver DNA coding for vaccine antigens and an adjuvant selected to activate the immune system. An antigen is a viral or bacterial protein that stimulates an immune response to the targeted pathogen.
Employees
65
Date Price Change Volume
21/10/26 $0.4750 -3.06% 117,102
20/10/26 $0.4900 +3.05% 89,499
19/10/26 $0.4755 +5.04% 792,161
16/10/26 $0.4527 -0.51% 201,772
15/10/26 $0.4550 -0.55% 184,782
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Vaxart, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.4750USD
Average target price
3.333USD
Spread / Average Target
+601.75%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Vaxart, Inc.
  1. Stock Market
  2. Stocks
  3. VXRT Stock